Synlogic

Synlogic Revenue

The revenue of Synlogic (SYBX) as of Nov 3, 2026.

Revenue

0.00USD

Last updated:

In 2025, Synlogic's sales reached 0.00 USD, a % difference from the 8,000.00 USD sales recorded in the previous year.

Revenue at Synlogic has contracted by 39.5% per year over the past 8 years to 8,000.00 USD.

The Synlogic Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
Date
Revenue
Jan 1, 2021
1.75 M USD
Jan 1, 2022
1.18 M USD
Jan 1, 2023
3.37 M USD
Jan 1, 2024
8,000.00 USD
Jan 1, 2025
0.00 USD
Jan 1, 2026 (e)
0.00 USD
Jan 1, 2027 (e)
83.24 M USD
Jan 1, 2028 (e)
232.99 M USD
The Synlogic Revenue history
YEARRevenueYoY
est232.99 MUSD+179.89%
est83.24 MUSD—
est0.00USD—
0.00USD-100.00%
8,000.00USD-99.76%
3.37 MUSD+185.68%
1.18 MUSD-32.73%
1.75 MUSD+221.83%
545,000.00USD-75.49%
2.22 MUSD-11.75%
2.52 MUSD+3.11%
2.44 MUSD+450.45%
444,000.00USD—
0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Synlogic Revenue

Synlogic Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
1.75 M USD
-60.77 M USD
-58.12 M USD
Jan 1, 2022
1.18 M USD
-67.42 M USD
-66.15 M USD
Jan 1, 2023
3.37 M USD
-55.16 M USD
-57.28 M USD
Jan 1, 2024
8,000.00 USD
-40.95 M USD
-23.36 M USD
Jan 1, 2025
0.00 USD
-4.01 M USD
-1.01 M USD
Jan 1, 2026 (e)
0.00 USD
-2.83 M USD
0.00 USD
Jan 1, 2027 (e)
83.24 M USD
-15.14 M USD
-14.39 M USD
Jan 1, 2028 (e)
232.99 M USD
95.69 M USD
71.84 M USD

Synlogic Margins

Synlogic stock margins

The Synlogic margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Synlogic. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Synlogic.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
100.00 %
-3,464.37 %
-3,313.46 %
Jan 1, 2022
100.00 %
-5,713.47 %
-5,605.68 %
Jan 1, 2023
100.00 %
-1,636.34 %
-1,699.26 %
Jan 1, 2024
100.00 %
-511,875.00 %
-291,987.48 %
Jan 1, 2025
100.00 %
- %
- %
Jan 1, 2026 (e)
100.00 %
- %
0.00 %
Jan 1, 2027 (e)
100.00 %
-18.19 %
-17.29 %
Jan 1, 2028 (e)
100.00 %
41.07 %
30.83 %

Synlogic Stock analysis

What does Synlogic do? Synlogic, Inc. develops synthetic biotic medicines using its proprietary Synthetic Biotic platform to treat rare genetic diseases such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). The company focuses on inborn errors of metabolism (IEM) and other conditions including inflammatory bowel disease, cancer, and metabolic disorders like diabetes and obesity. SYNB1020 targets UCD and hepatic encephalopathy (HE), while SYNB1618 is designed for PKU treatment. The firm operates as a clinical-stage biopharmaceutical company with a pipeline centered on genetically reengineered probiotics that perform missing or damaged functions due to disease. Synlogic's revenue model is based on developing and advancing clinical-stage therapies for rare and complex conditions. The company's pipeline includes SYNB1020 and SYNB1618, which are in development for specific disease indications. As a clinical-stage biopharmaceutical firm, Synlogic generates value through the progression of its drug candidates toward regulatory approval and potential commercialization. The company's focus on rare genetic diseases and metabolic conditions positions it to address unmet medical needs in specialized therapeutic areas. Synlogic targets patients with rare genetic disorders such as UCD and PKU, as well as those suffering from inflammatory bowel disease, cancer, and metabolic conditions including diabetes and obesity. The company's synthetic biotic approach aims to provide novel therapeutic solutions where traditional treatments may be insufficient. By leveraging synthetic biology to reengineer probiotics, Synlogic addresses critical medical gaps in the treatment of these complex conditions, focusing on both rare and broader metabolic disease markets. Synlogic is one of the most popular companies on Eulerpool.

Revenue Details

Understanding Synlogic's Sales Figures

The sales figures of Synlogic originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Synlogic’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Synlogic's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Synlogic’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Synlogic stock

On Eulerpool you can find the complete historical development of The revenue Synlogic since 2006 – with annual values, charts, and detailed analysis.

Revenue is the total value of all goods sold in a period. It is calculated by multiplying the quantity of each product sold by its selling price. Revenue does not include any costs (material costs, personnel costs, etc.), whereas net proceeds only deduct revenue reductions associated with the sale (discounts, etc.).

The revenue's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The revenue's Synlogic historically and in real time.

The revenue in assessing a stock

Revenue is an important financial measure used in the valuation of stocks. It is a measure of a company's economic activity and can serve as an indicator of the company's success. Revenue is considered one of the most important factors in stock valuation. In addition, revenue can also be used to calculate other financial measures such as earnings per share and price-earnings ratio.

History and utilization of revenue

Revenue has long been considered one of the most important financial indicators. It was used in the 19th century as one of the first financial indicators to measure a company's economic activity. Since then, revenue has been regularly used to evaluate companies.

Revenue is usually calculated as a percentage of the company's equity. It can also be used to determine the overall profitability of a company. There are many different types of revenue that can be used to measure a company's economic activity, such as gross revenue, net revenue, and revenue from international business.

The revenue can also be used to evaluate stocks. For example, the revenue of a company can be used to evaluate the success of the company. If a company has high revenue, it means that it is a profitable company because it has high demand for its products or services.

Calculation and Application of Revenue

In order to calculate a company's revenue, the company's income must be deducted from its expenses. The income can come from various sources, such as sales, licensing fees, services, etc. The expenses can include costs for production, procurement, inventory, sales, and administration.

The revenue can then be used to calculate various financial ratios. For example, the revenue can be used to calculate the price-earnings ratio (P/E ratio) of a company. This is a measure of a company's profitability, calculated by taking the ratio of the stock price to earnings per share.

Revenue can also be used to calculate earnings per share (EPS) of a company. This is a measure of a company's profit per share. EPS is calculated by dividing earnings by the number of shares issued.

Use of revenue by investors

Investors use revenue to evaluate stocks, as revenue is an indicator of a company's success. For example, an investor can compare a company's revenue to see how successful it is. An investor can also use a company's revenue to calculate its price-to-earnings ratio and earnings per share.

An example: An investor looks at a company that has a revenue of 25 million euros. He compares this revenue to that of the competitor, which has a revenue of 35 million euros. The investor can then see that the company with 25 million euros in revenue is less successful than the company with 35 million euros in revenue.

Advantages and Disadvantages of Revenue.

Revenue is a very useful tool for valuing stocks as it measures a company's economic activity. Revenue can also be used to calculate other financial ratios such as the price-earnings ratio and earnings per share.

However, one disadvantage is that revenue alone is not a meaningful indicator of a company's success. It is important to consider revenue in comparison to other financial metrics such as earnings per share and price-to-earnings ratio to get a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Synlogic

All Key Metrics — Synlogic